Strides Pharma Consolidates European Business-to-Business Operations in Switzerland

Share
  • Market proximity of Strides Pharma International AG, based in Zug, Switzerland, opens the way for rapid technology transfer and innovation within the European market
  • Oren Weininger, longstanding leader at Fairmed Healthcare, heads the business as CEO and Chairman of the Board
Oren Weininger, CEO Copyright Strides Pharma International AG.
Oren Weininger, CEO Copyright Strides Pharma International AG.

Zug, Switzerland. Strides Pharma Science Limited, globally recognized as a leading pharmaceutical company operating across 100 countries and headquartered in Bangalore, India, is consolidating its European business through Strides Pharma International AG, based in Zug, Switzerland.

Strides Pharma specializes in the development and manufacturing of IP-led niche finished dosage formulations. With over three decades of research and development expertise, Strides Pharma continuously develops and delivers products with innovative and improved technologies at competitive prices. Notably, Strides Pharma is among the world's largest manufacturers of Ibuprofen and Macrogol in various forms. Their unique range of drug delivery technologies opens up versatile and lucrative opportunities within the ever-evolving target markets.

The partner-centric in-licensing portfolio of over 250 formulations is consolidated in synergICE as a one-stop shop. It includes generics, sterile injectables and value-added products, Women´s Health hormones, lyophilized orally dissolving tablets and end-to-end biopharmaceutical CDMO services.

Oren Weininger, newly appointed Chairman of the Board, stated, “With this strengthened European B2B presence, we can respond faster to our customers’ needs and provide flexible, innovative solutions, and interesting generic portfolio, including comprehensive support in supply chain & quality management and regulatory processes by Strides Pharma International and the EU GMP-site in Hamburg, Germany.”

Key Markets are Central and Southern Europe (especially Germany), Scandinavia, Benelux and the Visegrád countries.

For further information, please visit: www.fair-med.com/newsroom

Contact Agency What About Now, Andreas Schöpf
as@whataboutnow.de Tel. +49 160 90723690

Following his roles at Dexcel Pharma and Kamedis, Oren Weininger took the position of CEO at Fairmed Healthcare AG in 2014 and subsequently became owner in 2018. Strides Pharma, after a period of successful partnership, invested in the company in 2019, further bolstering leading Fairmed Healthcare product lines. In addition to being appointed Chairman of the Board of Strides Pharma International AG, Weininger continues to lead Fairmed Healthcare GmbH in Hamburg.

Strides Pharma Science Limited, headquartered in Bangalore, India, was incorporated in 1990. The company has a global manufacturing footprint with eight facilities spread across four continents and a strong presence in 100 countries. Strides Pharma is a key active pharmaceutical ingredient manufacturer and producer of various products; every fourth Ibuprofen tablet on the global market today is supplied by Strides Pharma.

Images

Oren Weininger, CEO Copyright Strides Pharma International AG.
Oren Weininger, CEO Copyright Strides Pharma International AG.
Download

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Good overall result and revenue growth for the ZEISS Group17.12.2024 10:45:00 CET | Press release

ZEISS Group revenue increased to just under 11 billion euros (10.894 billion euros), (up 8% on the prior year) – EBIT 1,444 million euros (prior year: 1,686 million euros, EBIT margin 13%). Mixed development in the segments. High spend on research and development equivalent to 15% of revenue, more than 46,000 employees worldwide. Increasingly challenging market environment for the direct-to-market segments Strong growth in the Semiconductor Manufacturing Technology segment Outlook requires reinforcement of resilience measures

Bertelsmann Stiftung: Climate neutrality: The OECD and EU countries best equipped to lead the way17.12.2024 08:00:00 CET | Press release

How determined are OECD and EU countries in pursuing the goal of climate neutrality by 2050? A recent monitoring report by the Bertelsmann Stiftung reveals that Sweden, Denmark, Finland and Spain are setting the pace with their effective policy strategies. In contrast, Canada, Australia, Israel, Poland and Hungary need to significantly ramp up their efforts. The analysis compares the effectiveness of national policies in climate protection, energy transition and circular economy practices.

Bertelsmann Stiftung: More than half of all young people in the EU feel lonely16.12.2024 08:00:00 CET | Press release

Gütersloh, 16.12.2024. Many young adults in the EU share the feeling that they are lonely. Around 57 per cent of young Europeans aged from 18 to 35 feel moderately or strongly lonely, according to a new Bertelsmann Stiftung study entitled “Loneliness of Young People Compared across Europe in 2024.” The data for the EU-wide survey derive from the European opinion research tool eupinions.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye